Cargando…
A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
BACKGROUND: Schizophrenia is a severe, long-term neurodevelopmental disorder that results in increased morbidity and mortality. Amisulpride and Paliperidone are two antipsychotics used to treat schizophrenia in the UK. This evaluation compares the cost-utility of each drug; no similar research has b...
Autores principales: | Abdall-Razak, Ali, Macaulay, Alex, Tiefenbach, Jakov, Borges, Karen, Mathema, Sina, Zuberi, Sameer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819947/ https://www.ncbi.nlm.nih.gov/pubmed/31687534 http://dx.doi.org/10.1016/j.heliyon.2019.e02343 |
Ejemplares similares
-
Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
por: Luo, Rui, et al.
Publicado: (2023) -
Update on the management of symptoms in schizophrenia: focus on amisulpride
por: Mortimer, Ann M
Publicado: (2009) -
PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016) -
Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs
por: Bramante, Stefano, et al.
Publicado: (2023) -
Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)